Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.

Ficorella C, Bruera G, Cannita K, Porzio G, Baldi PL, Tinari N, Natoli C, Ricevuto E.

Clin Colorectal Cancer. 2012 Dec;11(4):229-37. doi: 10.1016/j.clcc.2012.05.001. Epub 2012 Jun 12. Review.

PMID:
22694897
2.

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.

Jpn J Clin Oncol. 2007 Sep;37(9):686-91. Epub 2007 Aug 24.

PMID:
17720736
3.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
4.

New systemic frontline treatment for metastatic colorectal carcinoma.

Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P.

Cancer. 2004 Apr 15;100(8):1558-77. Review.

6.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A.

J Clin Oncol. 2005 Jan 20;23(3):502-9.

PMID:
15659495
7.

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.

Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Cóppola F, Van Kooten M, Rodger J, Giglio R, Balbiani L, Perazzo F, Montiel M, Chacón M, Pujol F, Mickiewicz E, Cazap E, Recondo G, Lastiri F, Simon J, Wasserman E, Schmilovich A.

Eur J Cancer. 2001 May;37(8):1006-13.

PMID:
11334726
8.

Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.

deBraud F, Munzone E, Nolè F, De Pas T, Biffi R, Brienza S, Aapro MS.

Am J Clin Oncol. 1998 Jun;21(3):279-83.

PMID:
9626798
9.

The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.

Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R.

Tumori. 2000 Nov-Dec;86(6):465-9.

PMID:
11218187
10.

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O.

J Clin Oncol. 2004 Jan 1;22(1):31-8.

PMID:
14701765
11.

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.

Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E.

Clin Colorectal Cancer. 2005 Mar;4(6):384-9.

PMID:
15807931
12.

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.

Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A.

Br J Cancer. 2001 Nov 2;85(9):1258-64.

13.

A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.

Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ.

Cancer Invest. 2003;21(4):505-11.

PMID:
14533439
14.

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.

J Clin Oncol. 2004 Dec 1;22(23):4753-61. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570076
15.

5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.

Falcone A, Allegrini G, Masi G, Lencioni M, Pfanner E, Brunetti I, Danesi R, Bocci G, Del Tacca M, Conte P.

Oncology. 2001;61(1):28-35.

PMID:
11474245
16.

The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.

Matsushita H, Tsuboi K, Honda I, Kato N, Okochi O, Kobayashi D, Hattori M.

Gan To Kagaku Ryoho. 2009 May;36(5):797-801.

PMID:
19461180
18.
19.

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.

Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declère A, et al.

Cancer. 1992 Feb 15;69(4):893-900.

20.

[Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].

Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević A.

Srp Arh Celok Lek. 1998 Sep-Oct;126(9-10):355-61. Serbian.

PMID:
9863407

Supplemental Content

Support Center